From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including:

• How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe
• Practical sequencing decisions after disease progression
• Emerging BTK degradersas a promising option for heavily pretreated patients

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Nelson Hamerschlak, MD, PhD
Head of the Department of Hematology, BMT and Clinical Cell Therapy
Einstein Hospital Israelita
Sao Paulo, Brazil

Stephen Stilgenbauer, MD
Medical Director, Comprehensive Cancer Center Ulm (CCCU)
Head, Early Clinical Trials Unit (ECTU)
Head, Division of CLL Department of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
University of Medical Center Ulm
Ulm, Germany

Link to the full program: 
https://bit.ly/4rsZlqF

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.